Luciani Silvana, Bruni Laia, Agurto Irene, Ruiz-Matus Cuauhtémoc
Unit of Noncommunicable Diseases, Department of Noncommunicable Diseases and Mental Health, Pan American Health Organization. Washington, DC, USA.
Cancer Epidemiology Research Program, Catalan Institute of Oncology. Barcelona, Spain.
Salud Publica Mex. 2018 Nov-Dic;60(6):683-692. doi: 10.21149/9090.
To describe HPV vaccine program implementation, monitoring and evaluation experiences in Latin America.
We reviewed published articles in peer-reviewed journals and reports from government web- sites, as well as the PAHO/WHO/UNICEF Joint Reporting form and the ICO/IARC HPV Information Centre database.
By December 2016, 13 countries/territories in Latin America (56%) have introduced HPV vaccines. The majority have done so in the past three years, targeting 10- 12 year old girls with a two dose schedule, through school programs. Vaccine coverage ranges from 30 to 87%. Safety monitoring is well established, but monitoring vaccine impact is not, and data are not available.
. Although Latin America is the most advanced developing region with HPV vaccine introduction, systems for its monitoring are weak and there is a paucity of consistently available coverage data for this vaccine. Challenges remain to introduce HPV vaccines in several countries, to achieve high coverage, and to strengthen monitoring, evaluation and reporting.
描述拉丁美洲人乳头瘤病毒（HPV）疫苗项目的实施、监测及评估经验。
我们查阅了同行评审期刊上发表的文章、政府网站的报告，以及泛美卫生组织/世界卫生组织/联合国儿童基金会联合报告表和国际癌症研究机构（ICO/IARC）HPV信息中心数据库。
截至2016年12月，拉丁美洲的13个国家/地区（占56%）已引入HPV疫苗。大多数国家/地区在过去三年中通过学校项目为10至12岁女孩实施两剂次接种计划引入了该疫苗。疫苗接种率在30%至87%之间。安全监测体系完善，但疫苗影响监测不完善，且缺乏相关数据。
尽管拉丁美洲是引入HPV疫苗最先进的发展中地区，但其监测系统薄弱，且缺乏该疫苗持续可用的接种率数据。在一些国家引入HPV疫苗、实现高接种率以及加强监测、评估和报告方面仍存在挑战。
